Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents	$ 28,918	$ 17,116
Prepaid expenses and other current assets	593	827
Total Current Assets	29,511	17,943
Property and equipment, net	607	872
Deposits and other assets	23	23
Total Assets	30,141	18,838
Current Liabilities:
Accounts payable	1,034	2,020
Accrued expenses	919	1,526
Warrant liabilities	0	4,083
Accrued employee benefits	1,332	2,074
Deferred rent	99	90
Total Current Liabilities	3,384	9,793
Long term deferred rent	302	402
Total Liabilities	3,686	10,195
Commitments and Contingencies
Series A convertible preferred stock, $0.001 par value; 10,000,000 and zero shares authorized;120,000 issued and outstanding	12,296	12,053
Stockholders' Equity (Deficit):
Common stock, $0.001 par value; 250,000,000 and 10,000,000 shares authorized, 15,484,411, issued and 15,482,083 outstanding and 3,673,342 issued and 3,671,014 outstanding	15	4
Additional paid-in capital	230,754	192,670
Accumulated deficit	(219,461)	(194,170)
Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)	17,068	(1,496)
Non-controlling interest	(2,909)	(1,914)
Total Stockholders' Equity (Deficit)	14,159	(3,410)
Total Liabilities and Stockholders' Equity (Deficit)	30,141	18,838
Series B Preferred Stock [Member]
Stockholders' Equity (Deficit):
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 15,723 issued and 9,161 outstanding	5,760	0
Total Stockholders' Equity (Deficit)	$ 5,760	$ 0